Literature DB >> 20580909

Tramadol acts as a weak reinforcer in the rat self-administration model, consistent with its low abuse liability in humans.

Eoin C O'Connor1, Andy N Mead.   

Abstract

Rodent models of abuse potential are considered to represent a false positive with respect to the low risk of abuse liability associated with the atypical opioid analgesic tramadol. This may reflect either the predictive limitations of the models used to formulate this proposition (drug discrimination and conditioned place preference) or the predictive ability of the rodent per se. To address this concern, we used the rat self-administration model to examine the reinforcing properties of tramadol (0.3-3mg/kg/infusion) under fixed (FR) and progressive-ratio (PR) schedules of reinforcement. Comparisons were made with the typical opioid analgesics morphine (0.03-0.3mg/kg/infusion) and remifentanil (0.001-0.03mg/kg/infusion). All three compounds maintained responding under an FR3 schedule of reinforcement, although clear differences were observed in the rates of responding between compounds. Under a PR schedule, morphine and remifentanil maintained comparable break points, while break points for tramadol did not differ from vehicle. Thus, when examined in the self-administration model, tramadol acts as a relatively weak reinforcer in rodents. These data are consistent with the low risk of tramadol abuse liability in humans and highlight the value of using multiple abuse potential models for assessing abuse liability. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20580909     DOI: 10.1016/j.pbb.2010.05.018

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  12 in total

1.  Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.

Authors:  Kelly E Dunn; D Andrew Tompkins; George E Bigelow; Eric C Strain
Journal:  JAMA Psychiatry       Date:  2017-09-01       Impact factor: 21.596

2.  Pharmacodynamic profile of tramadol in humans: influence of naltrexone pretreatment.

Authors:  William W Stoops; Michelle R Lofwall; Paul A Nuzzo; Lori B Craig; Anthony J Siegel; Sharon L Walsh
Journal:  Psychopharmacology (Berl)       Date:  2012-05-24       Impact factor: 4.530

3.  Enhanced Recovery Protocol for Laparoscopic Sleeve Gastrectomy: Are Narcotics Necessary?

Authors:  Richard S Hoehn; Aaron P Seitz; Kathleen E Singer; Jonathan R Thompson; Brad M Watkins
Journal:  J Gastrointest Surg       Date:  2019-01-28       Impact factor: 3.452

4.  Cross state-dependency of learning between tramadol and MK-801 in the mouse dorsal hippocampus: involvement of nitric oxide (NO) signaling pathway.

Authors:  Majid Jafari-Sabet; Shiva Amiri; Ramin Ataee
Journal:  Psychopharmacology (Berl)       Date:  2018-04-21       Impact factor: 4.530

5.  Effects of the NOP agonist SCH221510 on producing and attenuating reinforcing effects as measured by drug self-administration in rats.

Authors:  Devki D Sukhtankar; Carla H Lagorio; Mei-Chuan Ko
Journal:  Eur J Pharmacol       Date:  2014-10-29       Impact factor: 4.432

6.  Punishment and reinforcement by opioid receptor agonists in a choice procedure in rats.

Authors:  Vanessa Minervini; Daniela C Osteicoechea; Angelo Casalez; Charles P France
Journal:  Behav Pharmacol       Date:  2019-06       Impact factor: 2.293

7.  Discriminative stimulus effects of tramadol in humans.

Authors:  Angela N Duke; George E Bigelow; Ryan K Lanier; Eric C Strain
Journal:  J Pharmacol Exp Ther       Date:  2011-04-05       Impact factor: 4.030

Review 8.  Revisiting Tramadol: A Multi-Modal Agent for Pain Management.

Authors:  Ahmed Barakat
Journal:  CNS Drugs       Date:  2019-05       Impact factor: 5.749

9.  Abuse liability and reinforcing efficacy of oral tramadol in humans.

Authors:  Shanna Babalonis; Michelle R Lofwall; Paul A Nuzzo; Anthony J Siegel; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2012-10-23       Impact factor: 4.492

10.  Designing opioids that deter abuse.

Authors:  Robert B Raffa; Joseph V Pergolizzi; Edmundo Muñiz; Robert Taylor; Jason Pergolizzi
Journal:  Pain Res Treat       Date:  2012-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.